|
시장보고서
상품코드
2051017
듀센형 근이영양증 치료 시장 : 치료 접근법 및 치료법별, 최종사용자별, 지역별Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography |
||||||
듀센형 근이영양증 치료 시장은 2026년에 133억 780만 달러로 추정되며, 2033년에 2,074억 7,420만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 48.0%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 133억 780만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 48.00% | 2033년 시장 규모 예측: | 2,074억 7,420만 달러 |
듀센형 근이영양증(DMD)은 근이영양증의 일종입니다. 이는 근육세포의 건강한 상태를 유지하는 역할을 하는 '디스트로핀'이라는 단백질의 이상으로 인해 진행성 근위축과 근력저하가 특징인 유전성 질환입니다. DMD는 근육에 영향을 미치고 시간이 지남에 따라 악화되는 근위축을 유발합니다. 듀센형 근이영양증은 주로 남성에게 발병하지만, 드물게 여성에게도 발병할 수 있습니다.
시장 역학
듀센형 근이영양증(DMD) 유병률 증가, 새로운 약물 및 치료법에 대한 수요 증가, 연구 개발(R&D) 활성화, DMD 및 사용 가능한 약물 및 치료법에 대한 인식 증가는 세계 듀센형 근이영양증 치료제 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다. 시장 성장을 촉진할 것으로 예상되는 주요 요인으로 꼽힙니다.
예를 들어, 2022년 5월 스텔스 바이오테라퓨틱스는 미국 식품의약국(FDA)이 듀센형 근이영양증(DMD) 치료제로 엘라미프레티드를 희귀질환 치료제로 지정했다고 발표했습니다.
또한, 2022년 4월, 화이자는 보행이 가능한 듀센형 근이영양증(DMD) 환자를 대상으로 한 미니 디스트로핀 유전자 치료제 '폴라디스트로겐 모바파르보벡'을 평가하는 임상 3상 시험에서 미국 내 첫 번째 시험 시설을 개설할 계획을 세웠습니다. 계획을 세웠습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 기업의 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 듀센형 근이영양증 치료제 시장의 주요 기업을 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 듀센형 근이영양증 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 듀센형 근이영양증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 듀센형 근이영양증 치료 시장 : 치료 접근법 및 치료법별, 2021-2033년
제5장 세계의 듀센형 근이영양증 치료 시장 : 최종사용자별, 2021-2033년
제6장 세계의 듀센형 근이영양증 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.16Duchenne Muscular Dystrophy Treatment Market is estimated to be valued at USD 13,307.8 Mn in 2026 and is expected to reach USD 207,474.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 48.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 13,307.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 48.00% | 2033 Value Projection: | USD 207,474.2 Mn |
Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.
Market Dynamics
Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.
For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).
Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.
Market Segmentation
- Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type (Revenue, USD Mn, 2021 - 2033)
- Molecular-based Therapies
- Steroid Therapy
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Other Therapeutic Approaches and Treatment Types
- Global Duchenne Muscular Dystrophy Treatment Market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals/Clinics
- Ambulatory Centers
- Other End Users
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Pfizer Inc.
- Fibrogen Inc.
- BioMarin
- Sarepta Therapeutics
- Santhera Pharmaceuticals
- PTC Therapeutics
- NS Pharma Inc.
- Nobelpharma Co. Ltd.
- Bristol-Myers Squibb
- Eli Lilly and Company
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Approach and Treatment Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in prevalence of Duchenne muscular dystrophy
- Lack of standardization and stringent rules/regulations
- Increase in demand for novel drugs or therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Molecular-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Steroid Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Other Therapeutic Approaches and Treatment Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals/Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Other End Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Global Duchenne Muscular Dystrophy Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
7. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fibrogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioMarin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Santhera Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NS Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nobelpharma Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
